Carlo Rosa


“The acquisition of Luminex represents an important step in the expansion strategy of DiaSorin. Today, we begin a new phase of our growth, that will position DiaSorin as a fully-fledged diagnostic and life science player, that can offer increasingly sophisticated solutions to customers worldwide, also via the integration of the multiplexing technology that Luminex has pioneered globally."

Milestones of the acquisition process

April 11, 2021 - Signing of the definitive merger agreement 

Press release

July 9, 2021 - Fulfillment of regulatory requirements for the acquisition of Luminex

Press release

July 14, 2021 - Completion of the acquisition

Press release